Archive for the ‘Clinical Trials / Drug Trials’ Category

Nexavar Dropped From Lung Cancer Trial

Wednesday, February 20th, 2008

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have stopped a late stage trial of their cancer drug Nexavar (sorafenib) in patients with nonsmall-cell lung cancer (NSCLC), because it was not showing the hoped for increase in survival. Following a planned interim analysis, the trial's independent data monitoring committee (DMC) concluded that the ...

Nexavar Dropped From Lung Cancer Trial

Tuesday, February 19th, 2008

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have stopped a late stage trial of their cancer drug Nexavar (sorafenib) in patients with nonsmall-cell lung cancer (NSCLC), because it was not showing the hoped for increase in survival. Following a planned interim analysis, the trial's independent data monitoring committee (DMC) concluded that the ...

How Our Bodies Keep Time

Saturday, February 9th, 2008

Our alarm clocks may spring forward on March 9, but our biological clocks may take longer to adjust. That's because our internal clocks are so tightly wound to many physiological and behavioral processes. Researchers have learned that circadian rhythms the 24-hour cycles that keep our bodies on time are involved in ...

New Single Research Contract Aims To Speed Up Contracting Process For Industry-sponsored Trials, UK

Monday, October 29th, 2007

The Department of Health introduces the new Contract Research Organisation model Clinical Trial Agreement (CRO mCTA). This replaces the many different contracts companies had to negotiate with individual hospital trusts. This new type of agreement marks another positive step to develop the NHS as a world-class environment for health research in ...

HHS OIG Report Cites Problems With FDA Oversight Of Clinical Trials

Monday, October 1st, 2007

FDA does not take adequate action to ensure the safety of millions of participants in clinical trials, according to a report from the HHS Office of Inspector General scheduled for release on Friday, the New York Times reports. According to the report, written by HHS Inspector General Daniel Levinson, FDA -- ...

Summary Results Of Phase 1 Metastatic Melanoma Study Released By Provectus Pharmaceuticals, Inc.

Thursday, September 20th, 2007

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced preliminary results of its Phase 1 clinical trial of Provecta for the treatment of metastatic melanoma, the most aggressive form of skin cancer. Provecta demonstrated minimal side effects, significant efficacy and bystander effect on melanoma tumors in stage III patients. The study evaluated safety ...

Chemotherapy For Advanced Colorectal Cancer Prolongs Survival Of Patients

Thursday, September 20th, 2007

Modern chemotherapy treatment for advanced colorectal cancer, such as irinotecan, oxaliplatin, and molecular-targeted treatments, are successful in extending the lives of patients by several months - not the case a few years ago when these treatments were unavailable, says a report in The Lancet Oncology September 20th Edition. Professor Loennidis, University ...

Legislation Targets Public Disclosure Of Clinical Trial Data On Experimental Drugs

Wednesday, September 19th, 2007

Congress, industry experts and advocacy groups continue to disagree on how best to create a system for releasing clinical trial data to the public, a measure that is part of broader legislation that would expand FDA oversight of prescription drug safety and reauthorize the Prescription Drug User Fee Act, the ...

Avastin Approved In Europe For First-line Treatment Of Patients With Advanced Lung Cancer

Saturday, August 25th, 2007

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy. NSCLC is the most common form of lung cancer, a difficult to treat disease that kills over 3,000 people per day worldwide.(1) ...